Satellos Bioscience Inc. has seen notable stock performance this week, driven by recent developments in its clinical programs.
This week, Satellos Bioscience Inc. (MSCL.TO) experienced a positive price movement, with shares gaining 11.17% over the week. The stock closed at C$13.93, reflecting a 0.58% increase on the last trading day. Investors may be interested in the company's recent achievements and how they might impact future performance.
Investor takeaway: Satellos is making strides in its clinical development, particularly with the FDA Fast Track designation for its lead candidate, SAT-3247. This designation may accelerate its pathway to market, which is a positive signal for investors.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$293.85M
52W high
$18.98
52W low
$7.32
1W change
+11.17%
Beta
1.14
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 26.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+26.8% Upside
Current Price
C$13.93
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
50.7%
Annualized
90-Day Vol
72.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.65
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$14.78 | C$12.41 โ C$17.61 |
| 60 trading days | C$15.69 | C$12.25 โ C$20.09 |
| 90 trading days | C$16.65 | C$12.30 โ C$22.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Stock Performance Highlights
The stock has appreciated 65.83% year-to-date, reflecting growing investor interest amidst its clinical progress.
Bull case
The FDA Fast Track designation for SAT-3247 could speed up development timelines, boosting investor confidence. Additionally, positive updates from clinical trials could further support the company's potential in treating Duchenne muscular dystrophy.
Bear case
Despite recent gains, Satellos has a negative return on equity and a profit margin of 0.0%, indicating ongoing financial challenges. Investors should be cautious of potential volatility as the company navigates its clinical programs and market conditions.
Recent Price Action
Advertisement
Satellos Bioscience Inc. (MSCL.TO) closed at C$13.93 on the last trading day, marking a 0.58% increase. Over the past week, the stock has risen 11.17%, showcasing strong momentum. Year-to-date, the stock has appreciated significantly by 65.83%, indicating a positive trend in investor sentiment.
Company Developments
While there were no major news releases this week, recent headlines indicate that Satellos received FDA Fast Track designation for its lead candidate, SAT-3247, aimed at treating Duchenne muscular dystrophy. This designation is crucial as it facilitates faster development and review processes, possibly leading to earlier market entry.
Technical Picture
From a technical standpoint, the stock is currently trading above its 50-day moving average of C$12.88 and its 200-day moving average of C$11.23, indicating a bullish trend. The stock's 52-week range has been between C$7.32 and C$18.98, with the current price sitting at approximately 57% of that range. The stock has a beta of 1.14, suggesting it is slightly more volatile than the overall market. Recent trading volume was 10,503 shares, which is below the 20-day average volume of 12,832 shares, indicating a slight decrease in trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
